| Literature DB >> 35903342 |
Liang Kang1, Huaqing Zhang1, Chongyu Jia1, Renjie Zhang1, Cailiang Shen1.
Abstract
Low back pain is a major cause of disability worldwide that declines the quality of life; it poses a substantial economic burden for the patient and society. Intervertebral disc (IVD) degeneration (IDD) is the main cause of low back pain, and it is also the pathological basis of several spinal degenerative diseases, such as intervertebral disc herniation and spinal stenosis. The current clinical drug treatment of IDD focuses on the symptoms and not their pathogenesis, which results in frequent recurrence and gradual aggravation. Moreover, the side effects associated with the long-term use of these drugs further limit their use. The pathological mechanism of IDD is complex, and oxidative stress and inflammation play an important role in promoting IDD. They induce the destruction of the extracellular matrix in IVD and reduce the number of living cells and functional cells, thereby destroying the function of IVD and promoting the occurrence and development of IDD. Phytochemicals from fruits, vegetables, grains, and other herbs play a protective role in the treatment of IDD as they have anti-inflammatory and antioxidant properties. This article reviews the protective effects of phytochemicals on IDD and their regulatory effects on different molecular pathways related to the pathogenesis of IDD. Moreover, the therapeutic limitations and future prospects of IDD treatment have also been reviewed. Phytochemicals are promising candidates for further development and research on IDD treatment.Entities:
Keywords: inflammation; intervertebral disc degeneration; oxidative stress; phytochemicals; therapeutic implication
Year: 2022 PMID: 35903342 PMCID: PMC9315394 DOI: 10.3389/fphar.2022.956355
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.988
FIGURE 1Inflammation and oxidative stress are involved in multiple pathological processes of IDD.
Phytochemicals possess multiple pharmacological effects via the anti-inflammatory and antioxidant mechanism in various in vitro and in vivo models of IDD.
| Phytochemical | Study model | Dosage range | Signal pathways/Mechanisms | References |
|---|---|---|---|---|
| Curcumin |
| 5, 10, 15, 20, 25 μM | inhibited oxidative stress and mitochondrial dysfunction through AMPK/mTOR/ULK1 pathway-induced autophagy and -enhanced autophagic flux |
|
|
| 100 mg/kg | |||
| Resveratrol |
| 10, 50, 100, 200, 400 μM | inhibited SNP-induced NP cell apoptosis by reducing ROS production |
|
|
| 100 μM | |||
|
| 50 μM | reduced the expression levels of inflammatory factors in NP cells |
| |
| Mangiferin |
| 100 μM, 500 μM | inhibited NP cell apoptosis and ECM degeneration by inhibiting the production of inflammatory factors and ROS; NF-κB signaling pathway |
|
|
| 0.2 μg | |||
| (-)-Epigallocatechin-3-gallate |
| 5 μM, 25 μM | inhibited the expression level of inflammatory mediators and apoptosis; cGAS/Sting/NLRP3 pathway |
|
| Chlorogenic acid |
| 6.25, 12.5, 25 μM | inhibited the expression of inflammatory mediator and ECM degradation; NF-κB pathway |
|
| Icariin |
| 0.1, 1, 10 μM | inhibited the level of PGE2, NO, iNOS, COX-2 and ECM degradation; MAPK pathway and NF-κB pathway |
|
|
| 0.1, 1, 10 μM | inhibited the production of ROS induced by H2O2; alle |
| |
| Lycopene |
| 2.5 μm, 5 μm | Inhibited the apoptosis and ECM degradation; Nrf2 pathway |
|
| Celastrol |
| 10, 50, 100, 200 nM | Inhibited the apoptosis, ECM degradation, inflammation; NF-κB pathway |
|
| Isofraxidin |
| 10, 20, 40 μM | inhibited the level of PGE2, NO, iNOS, COX-2, TNF-α, and IL-6; NF-κB pathway |
|
| Higenamine |
| 10, 20, 40 μM | inhibited the level of PGE2, iNOS, COX-2, TNF-α, and IL-6; NF-κB pathway |
|
| Sesamin |
| 0.1, 0.5, 1 μM | suppressed the expression of inflammation factors and the migration of macrophages induced by LPS; MAPK pathway |
|
|
| 10 μg/ml | |||
|
| 0.1 M |
| ||
| Honokiol |
| 2.5μM, 5 μM | inhibited the production of oxidative stress marker molecules (ROS, MDA) and the level of inflammatory mediators (IL-6, COX-2 and iNOS) in NP cells; NF-κB pathway, JNK signal, TXNIP/NLRP3/caspase-1/IL-1β signal axis |
|
|
| 30 mg/kg | |||
|
| 1, 5, 10 μM | improved mitochondrial antioxidant capacity, mitochondrial function, and prevented oxidative stress in NP cells; AMPK-PGC-1α signaling pathway |
| |
|
| 40 mg/kg | |||
| Salvianolic acid B |
| 0.001, 0.01, 0.1, 1, 10, 100 nM | reduced the levels of ROS and MDA and increased the levels of GSH and SOD2 |
|
|
| 20 mg/kg | |||
| Polydatin |
| 200 μM, 400 μM | reduced the production of ROS through Nrf2 signaling pathway |
|
|
| 50 mg/kg | |||
|
| 200 μM | upregulated Parkin and Nrf2 pathway, protecting CEP cells from H2O2-induced mitochondrial dysfunction, oxidative stress and apoptosis |
| |
| Naringin |
| 5 μg/ml, 10 μg/ml, 20 μg/ml | prevented NP cells from inflammatory response, oxidative stress and impaired cellular homeostasis; AMPK/SIRT1 pathway |
|
| Baicalein |
| 5, 25, 50 μM | inhibited the level of NO, PGE2, TNF-α and IL-6 induced by IL-1β in NP cells; NF-κB and MAPK pathways |
|
|
| 20 mg/kg | |||
| Berberine |
| 1, 2, 4, 8 μM | inhibited oxidative stress-induced cell damage by regulating ER stress and autophagy; IRE1/JNK pathway |
|
|
| 150 mg/kg | |||
|
| 25 μM | inhibited inflammation-induced cell injury |
| |
| Genistein |
| 50 μM, 100 μM | inhibited TBHP-induced apoptosis and ECM degradation; Nrf2 pathway |
|
|
| 100 mg/kg/day via intragastric administration for 1 week before surgery | |||
| Acacetin |
| 0.3 μM, 1 μM | inhibited TBHP-induced ROS production in NP cells; reduced the expression of inflammatory mediators such as COX-2 and iNOS; Nrf2 and MAPK pathway |
|
|
| 25 mg/kg | |||
| Wogonin |
| 10, 25, 50 μM | Inhibited IL-1β-induced inflammatory response and extracellular matrix degradation in NP cells |
|
| Luteoloside |
| 2, 5, 10 μM | inhibited IL-1β-induced the level of NO, PGE2, TNF-α, IL-6, COX-2, and iNOS in rat NP cells; Nrf2/NF-κB pathway |
|
|
| 10 mg/kg | |||
| Quercetin |
| 5, 15, 30, 60 μM | reduced ROS by activating SIRT1-autophagy pathway |
|
|
| 100 mg/kg |